Jazz Pharmaceuticals plc JAZZ
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Joon Lee | Truist Financial | 124.865 $ | 205 $ | 80.14 % | 28/08/2025 |
| Gregory Renza | RBC Capital | 124.3612 $ | 151 $ | 26.64 % | 28/08/2025 |
| David Hoang | Deutsche Bank | 112.3 $ | 152 $ | 39.70 % | 15/07/2025 |
| Balaji Prasad | Barclays | 144.17 $ | 200 $ | 55.83 % | 27/02/2025 |
| Akash Tewar | Jefferies | 125.1 $ | 160 $ | 34.90 % | 21/11/2024 |
| Joel Beatty | Robert W. Baird | 122 $ | 162 $ | 40.00 % | 18/11/2024 |
| Daniel Busb | RBC Capital | 113.1 $ | 179 $ | 65.90 % | 23/10/2024 |
| Annabel Samimy | Stifel Nicolaus | 105.22 $ | 230 $ | 124.78 % | 11/09/2024 |
| Andrea Tan | Goldman Sachs | 104.48 $ | 169 $ | 64.52 % | 05/06/2024 |
| Daniel Busb | RBC Capital | 110.31 $ | 176 $ | 65.69 % | 02/05/2024 |
| David Amsellem | Piper Sandler | 124.79 $ | 188 $ | 63.21 % | 20/03/2024 |
| David Amsellem | Piper Sandler | 142.91 $ | 193 $ | 50.09 % | 21/06/2022 |
| Ashwani Verma | UBS | 141.59 $ | 194 $ | 52.41 % | 13/06/2022 |
| Ami Fadia | Needham | 152.9 $ | 215 $ | 62.10 % | 03/03/2022 |
| Greg Fraser | Truist Financial | 139.13 $ | 200 $ | 60.87 % | 20/01/2022 |
| Annabel Samimy | Stifel Nicolaus | 144.3 $ | 210 $ | 65.70 % | 14/01/2022 |
| Aaron Gal | Bernstein | 131.01 $ | 175 $ | 43.99 % | 03/01/2022 |
| Jason Gerberry | Bank of America Securities | 136.32 $ | 193 $ | 56.68 % | 10/11/2021 |
| Brandon Folkes | Cantor Fitzgerald | 136.91 $ | 210 $ | 73.09 % | 06/10/2021 |
| Navann Ty | Citigroup | 128.08 $ | 200 $ | 71.92 % | 05/10/2021 |
| Balaji Prasad | Barclays | 177.3 $ | 250 $ | 72.70 % | 22/06/2021 |
| Esther Rajavelu | UBS | 177.28 $ | 234 $ | 56.72 % | 18/06/2021 |
| Ken Cacciatore | Cowen & Co. | 176.1 $ | 200 $ | 23.90 % | 10/05/2021 |